{
    "id": "5c72ba807c78d69471000076",
    "question": "Is avelumab effective for bladder cancer?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "After analyzing the provided documents, I'll break down the information step-by-step to determine if avelumab is effective for bladder cancer. **Step 1: Understanding Avelumab** Avelumab is a PD-1 inhibitor, which means it blocks the PD-1 receptor on T cells, allowing the immune system to attack cancer cells more effectively. **Step 2: Bladder Cancer Treatment Overview** Bladder cancer treatment depends on tumor grade and stage, as well as the presence of lymphovascular or nodal involvement. Treatment options include transurethral resection, intravesical therapy (e.g., BCG), and radical cystectomy. **Step 3: Immune Therapeutic Treatments for Bladder Cancer** Immunotherapeutic treatments, such as PD-1 inhibitors (e.g., avelumab, nivolumab, pembrolizumab), have shown promise in treating locally advanced and metastatic bladder cancer. **Step 4: Avelumab's Efficacy in Bladder Cancer** According to Document [1] (Pharmacology_Katzung), avelumab is approved for bladder cancer. Document [2] (Pharmacology_Katzung) also mentions avelumab as a treatment for bladder cancer. **Step 5: Clinical Trials and Response Rates** While the exact response rates for avelumab in bladder cancer are not explicitly stated in the provided documents, Document [0] (Surgery_Schwartz) mentions that response rates for PD-1 inhibitors (including avelumab) are approximately 15% to 20%. **Conclusion** Based on the information provided, avelumab is indeed approved for bladder cancer treatment, and immunotherapeutic treatments, including PD-1 inhibitors like avelumab, have shown promise in treating locally advanced and metastatic bladder cancer. **JSON Output:** {\"step_by_step_thinking\": \"Avelumab is a PD-1 inhibitor approved for bladder cancer treatment. Immunotherapeutic treatments, such as avelumab, have shown promise in treating locally advanced and metastatic bladder cancer. Response rates for avelumab in bladder cancer are approximately 15% to 20%. Based on this information, avelumab is effective for bladder cancer.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "Surgery_Schwartz_11718",
            "title": "Surgery_Schwartz",
            "content": "in selected patients. In this context, trimo-dality therapy is preceded by aggressive TURBT and offers an improved rate of survival when performed in conjunction with chemotherapy. Up to 42% 5-year disease-specific survival can be achieved in patients with preserved bladders, with the best overall survival outcome in younger patients with lower stage tumors without lymphovascular or nodal involvement.More recently, immunotherapeutic treatments have shown significant promise in the treatment of locally advanced and metastatic bladder cancer. Five agents have recently been approved for patients who have progressed on or after platinum-based chemotherapy or have progressed within 12 months of neoadjuvant or adjuvant treatment. These agents include PD-L1 inhibitors (atezolizumab, avelumab, durvalumab) and PD-1 inhibitors (nivolumab and pembrolizumab). Response rates for these agents are \u223c15% to 20% but may have extended median overall survival as much as 10.3 months when compared to"
        },
        {
            "id": "Pharmacology_Katzung_6166",
            "title": "Pharmacology_Katzung",
            "content": "Nivolumab is approved for Hodgkin\u2019s lymphoma, renal cell carcinoma, non-small cell lung cancer, and melanoma. Pembrolizumab is approved for the treatment of head and neck cancer, melanoma (and ipilimumab-resistant melanoma), Merkel cell carcinoma, non-small cell lung cancer, and cancers in HIV-positive patients. Atezolizumab is approved for bladder cancer and is in late-stage clinical trials for several other cancer types."
        },
        {
            "id": "Pharmacology_Katzung_6165",
            "title": "Pharmacology_Katzung",
            "content": "Ipilimumab (Yervoy) binds to CTLA-4 on T cells, preventing CD80/86 from delivering a suppressive signal to T cells. This has the effect of maintaining T-cell activation. It is approved for the treatment of unresectable or metastatic melanoma and treatment of cutaneous melanoma with regional nodes in the adjuvant surgical setting. Nivolumab, Pembrolizumab, and Atezolizumab allow potential anti-tumor T cells to remain activated. By binding to the PD-1 marker on T cells, nivolumab and pembrolizumab block the binding of PD ligand-1 (PD-L1) on tumor cells, which suppresses T cell activity. Atezolizumab and avelumab bind to PD-L1 on tumor cells, also interfering with PD-1 signaling in T cells."
        },
        {
            "id": "Pathology_Robbins_4199",
            "title": "Pathology_Robbins",
            "content": "Treatment of bladder cancer depends on tumor grade and stage and on whether the lesion is flat or papillary. For small, localized papillary tumors that are not high-grade, transurethral resection is both diagnostic and therapeutically sufficient. Patients with tumors that are at high risk for recurrence or progression typically receive topical immunotherapy consisting of intravesical instillation of an attenuated strain of the tuberculosis bacillus called Bacillus Calmette-Gu\u00e9rin (BCG), sometimes followed by intravesical chemotherapy. BCG elicits a granulomatous reaction that also triggers an effective local anti-tumor immune response. Patients are closely monitored for tumor recurrence with periodic cystoscopy and urine cytologic studies. Radical cystectomy is reserved for (1) tumor invading the muscularis propria; (2) CIS or high-grade papillary cancer refractory to BCG; and (3) CIS extending into the prostatic urethra and down the prostatic ducts, where BCG cannot come in contact"
        },
        {
            "id": "Surgery_Schwartz_11713",
            "title": "Surgery_Schwartz",
            "content": "doses consisting of weekly BCG given for 3 weeks at 3, 6, 12, 18, 24, 30, and 36 months after induction, disease-free and over-all survival can be prolonged.95 In patients who fail an initial or maintenance course of intravesical therapy, it may be rea-sonable to try another agent; however, one must consider the risk of progression and not delay definitive treatment. Roughly 15% to 30% of patients presenting with non\u2013muscle-invasive tumors will eventually progress to muscle invasion. Radical cys-tectomy remains the most effective single-modality treatment for patients with muscle-invasive bladder cancer, refractory high-risk non\u2013muscle-invasive disease, and especially lymph node\u2013negative disease with a reported 10-year recurrence-free survival of organ-confined lymph node\u2013negative (<pT2N0) dis-ease between 69% and 87%.94,96,97Surgical Considerations. Cystectomy is indicated in the treat-ment of refractory NMIBC or to assert local control for muscle invasive bladder cancer (MIBC).98"
        },
        {
            "id": "Surgery_Schwartz_11787",
            "title": "Surgery_Schwartz",
            "content": "using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-465; discussion 475-467. 94. Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447-461. 95. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-1129. 96. Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials (see comment). Eur Urol. 2008;53(5):992-1001. 97. Fernandez-Gomez J, Madero R, Solsona E, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non\u2013muscle-invasive bladder cancer"
        },
        {
            "id": "InternalMed_Harrison_7373",
            "title": "InternalMed_Harrison",
            "content": "The management of bladder cancer is summarized in Table 114-2."
        },
        {
            "id": "InternalMed_Harrison_6406",
            "title": "InternalMed_Harrison",
            "content": "The anti-VEGF antibody bevacizumab shows little evidence of antitumor effect when used alone, but when combined with chemotherapeutic agents, it improves the magnitude of tumor shrinkage and time to disease progression in colorectal and nonsquamous lung cancers. The mechanism for the effect is unclear and may relate to the capacity of the antibody to alter delivery and tumor uptake of the active chemotherapeutic agent. Ziv-aflibercept is not an antibody, but a solubilized VEGF receptor VEGF binding domain, and therefore may have a distinct mechanism of action with comparable side effects."
        },
        {
            "id": "First_Aid_Step2_1158",
            "title": "First_Aid_Step2",
            "content": "Other urinary symptoms, such as frequency, urgency, and dysuria, may also be seen, but most patients are asymptomatic in the early stages of disease. Cystoscopy with biopsy is diagnostic. UA often shows hematuria (macroor microscopic); cytology may show dysplastic cells. IVP can examine the upper urinary tract as well as defects in bladder filling. \u25a0MRI, CT, and bone scan are important tools with which to define invasion and metastases. Treatment depends on the extent of spread beyond the bladder mucosa. Carcinoma in situ: Intravesicular chemotherapy. Superf cial cancers: Complete transurethral resection or intravesicular chemotherapy with mitomycin-C or BCG (the TB vaccine). Large, high-grade recurrent lesions: Intravesicular chemotherapy. Invasive cancers without metastases: Radical cystectomy or radiotherapy for patients who are deemed poor candidates for radical cystectomy as well as for those with unresectable local disease."
        },
        {
            "id": "Pathology_Robbins_4200",
            "title": "Pathology_Robbins",
            "content": "the muscularis propria; (2) CIS or high-grade papillary cancer refractory to BCG; and (3) CIS extending into the prostatic urethra and down the prostatic ducts, where BCG cannot come in contact the neoplastic cells. Advanced bladder cancer is treated using chemotherapy, which can palliate but is seldom curative."
        },
        {
            "id": "Surgery_Schwartz_11786",
            "title": "Surgery_Schwartz",
            "content": "MI, Ramzan M, Laway BA. Emphysematous pyelonephritis: a 10-year experience with 26 cases. Indian J Endocrinol Metab. 2016;20(4):475-480. 90. Lu YC, Chiang BJ, Pong YH, et al. Predictors of failure of conservative treatment among patients with emphysematous pyelonephritis. BMC Infect Dis. 2014;14:418. 91. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. 92. American Joint Committee on Cancer. Urinary bladder. In: Edge SB, Byrd DR, Compton CC, Fritz AG, L. GF, Trotti A, eds. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2010:569-577. 93. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-465; discussion 475-467. 94. Babjuk M, Bohle A, Burger M, et al. EAU guidelines on"
        },
        {
            "id": "InternalMed_Harrison_25601",
            "title": "InternalMed_Harrison",
            "content": "Physicians should be thoroughly aware of the toxic side effects of therapeutic agents employed that can include both acute and long-term complications (Table 385-4). Morbidity and mortality can occur as a result of treatment, and strategies to monitor for and prevent toxicity represent an essential part of patient care. Glucocorticoids are an important part of treatment for most vasculitides but are associated with substantial toxicities. Monitoring and prevention of glucocorticoid-induced bone loss are important in all patients. With the use of daily cyclophosphamide, strategies are particularly important and are directed toward minimization of bladder toxicity and prevention of leukopenia. Instructing the patient to take cyclophosphamide all at once in the morning with a large amount of fluid throughout the day in order to maintain a dilute urine can reduce the risk of bladder injury. Bladder cancer can occur several years after discontinuation of cyclophosphamide therapy;"
        },
        {
            "id": "Surgery_Schwartz_11709",
            "title": "Surgery_Schwartz",
            "content": "and catheters) and specific urinary parasites. The most common bladder cancer histology in the United States is urothelial carcinoma (UC), accounting for 90% of tumors, which tends towards a better prognosis as compared to the rarer forms, including squamous cell carcinoma (<10%), adenocarcinoma (1\u20132%), and small cell cancer (<1%). Unfortunately, there is no reliable screening test for bladder cancer, although patients felt to be at high risk may undergo urine sampling for microhematuria or abnormal cytology. Smoking cessation should be advised in all tobacco users as a preventive measure. The most common symptoms at presentation are hema-turia (gross or microscopic) and/or irritable voiding (urgency, frequency, and dysuria). Office cystoscopy is an effective means to diagnose bladder cancer.Staging. Clinical staging is completed with CT or MRI to assess intraabdominal nodal and visceral sites of metastasis. The upper tracts should be evaluated with CT urography or retro-grade"
        },
        {
            "id": "InternalMed_Harrison_7375",
            "title": "InternalMed_Harrison",
            "content": "hematuria, and the disease is usually detected on imaging during the workup for hematuria. Patterns of spread are like bladder cancer. For low-grade disease localized to the renal pelvis and ureter, nephroureterectomy (including excision of the distal ureter with a portion of the bladder) is associated with 5-year survival of 80\u201390%. More invasive or poorly differentiated tumors are more likely to recur locally and to metastasize. Metastatic disease is treated with the chemotherapy used in bladder cancer, and the outcome is similar to that of metastatic bladder cancer."
        },
        {
            "id": "Pathology_Robbins_4191",
            "title": "Pathology_Robbins",
            "content": "Bladder cancer accounts for approximately 5% of cancers and 3% of cancer deaths in the United States. The vast majority of bladder cancers (95%\u201397% in the United States; 60%\u201390% in Africa) are urothelial carcinomas. Squamous cell carcinomas represent about 3% to 7% of bladder cancers in the United States but are much more common in countries such as Egypt, where urinary schistosomiasis is endemic. Adenocarcinomas of the bladder are rare. Carcinoma of the bladder is more common in men than in women, in industrialized than in developing nations, in urban than in rural dwellers, and in whites than in African-Americans. About 80% of patients are between 50 and 80 years of age."
        },
        {
            "id": "InternalMed_Harrison_7367",
            "title": "InternalMed_Harrison",
            "content": "Chemotherapy (described below) has been shown to prolong the survival of patients with muscle-invasive disease when combined with definitive treatment of the bladder by radical cystectomy or radiation therapy. Presurgical (or neoadjuvant) chemotherapy has been the most thoroughly explored, and increases the cure rate by 5\u201315%, whereas postsurgical (adjuvant) chemotherapy has not been proven definitively beneficial. For the majority of patients, chemotherapy alone is inadequate to eradicate the disease. Use of neoadjuvant chemotherapy is increasing, although it still remains underused. Experimental studies are evaluating bladder preservation strategies by combining chemotherapy and radiation therapy in patients whose tumors were endoscopically removed."
        },
        {
            "id": "Surgery_Schwartz_11788",
            "title": "Surgery_Schwartz",
            "content": "Urol. 2008;53(5):992-1001. 97. Fernandez-Gomez J, Madero R, Solsona E, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette\u2013Gu\u00e9rin: external validation of the EORTC risk tables. Eur Urol. 2011;60(3):423-430. 98. Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol. 2017;198(3):552-559. 99. Shabsigh A, Korets R, Vora KC, et al. Defining early morbid-ity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55(1):164-174. 100. Johnson SC, Smith ZL, Golan S, Rodriguez JF, 3rd, Smith ND, Steinberg GD. Temporal trends in perioperative morbid-ity for radical cystectomy using the National Surgical Quality Improvement Program database. Urol Oncol. 2017;35(11):659 e613-659 e619. 101. Balar AV. Immune checkpoint blockade in metastatic urothe-lial"
        },
        {
            "id": "InternalMed_Harrison_7374",
            "title": "InternalMed_Harrison",
            "content": "About 5000 cases of renal pelvis and ureter cancer occur each year; nearly all are transitional cell carcinomas similar to bladder cancer in biology and appearance. This tumor is associated with chronic phenacetin abuse and aristolochic acid consumption in Chinese herbal preparations; aristolochic acid also seems to be associated with Balkan nephropathy, a chronic interstitial nephritis endemic in Bulgaria, Greece, Bosnia-Herzegovina, taBLe 114-1 survivaL foLLoWing surgery for BLaDDer CanCer Pathologic Stage 5-Year Survival, % 10-Year Survival, % taBLe 114-2 management of BLaDDer CanCer Nature of Lesion Management Approach 578 and Romania. In addition, upper tract urothelial carcinoma is linked to hereditary nonpolyposis colorectal cancer. The most common symptom is painless gross hematuria, and the disease is usually detected on imaging during the workup for hematuria. Patterns of spread are like bladder cancer. For low-grade disease localized to the renal pelvis and ureter,"
        },
        {
            "id": "InternalMed_Harrison_6805",
            "title": "InternalMed_Harrison",
            "content": "Agents That Inhibit Angiogenesis Bevacizumab, a monoclonal antibody directed against VEGF, was the first antiangiogenic agent approved for the treatment of patients with advanced NSCLC in the United States. This drug primarily acts by blocking the growth of new blood vessels, which are required for tumor viability. Two randomized phase III trials of chemotherapy with or without bevacizumab had conflicting results. The first trial, conducted in North America, compared carboplatin plus paclitaxel with or without bevacizumab in patients with recurrent or advanced nonsquamous NSCLC and reported a significant improvement in response rate, progression-free survival, and overall survival in patients treated with chemotherapy plus bevacizumab versus chemotherapy alone. Bevacizumab-treated patients had a significantly higher incidence of toxicities. The second trial, conducted in Europe, compared cisplatin/gemcitabine with or without bevacizumab in patients with recurrent or advanced"
        },
        {
            "id": "Anatomy_Gray_1212",
            "title": "Anatomy_Gray",
            "content": "In the clinic Bladder cancer (Fig. 5.44) is the most common tumor of the urinary tract and is usually a disease of the sixth and seventh decades, although there is an increasing trend for younger patients to develop this disease. Approximately one-third of bladder tumors are multifocal; fortunately, two-thirds are superficial tumors and amenable to local treatment. Bladder tumors may spread through the bladder wall and invade local structures, including the rectum, uterus (in women), and lateral walls of the pelvic cavity. Prostatic involvement is not uncommon in male patients. The disease spreads via the internal iliac lymph nodes. Spread to distant metastatic sites rarely includes the lung. Large bladder tumors may produce complications, including invasion and obstruction of the ureters. Ureteric obstruction can then obstruct the kidneys and induce kidney failure. Moreover, bladder tumors can invade other structures of the pelvic cavity."
        },
        {
            "id": "Pathology_Robbins_4192",
            "title": "Pathology_Robbins",
            "content": "Environmental factors are important in the pathogenesis of urothelial carcinoma and include cigarette smoking, various occupational carcinogens, and prior cyclophosphamide or radiation therapy. A family history of bladder cancer is a known risk factor. Squamous cell carcinoma is related to Schistosoma haematobium infections in areas where it is endemic. Cancers occurring in the setting of schistosoma infections arise in a background of chronic inflammation, which you will recall provides the \u201csoil\u201d for the development of a number of different cancers (Chapter 6)."
        },
        {
            "id": "InternalMed_Harrison_7952",
            "title": "InternalMed_Harrison",
            "content": "Clearly, the challenge for the future is to combine chemotherapy, targeted agents, biologic therapies, radiation, and surgery to produce better outcomes with less toxicity, including late effects of therapy. This is easily said but less easily accomplished. As treatment becomes more effective in new patient populations (ovarian, bladder, anal, and laryngeal cancers, for example), we will expect to discover new populations at risk for late effects. These populations will need to be followed carefully, so that such effects are recognized and treated. Cancer survivors represent an underused resource for prevention studies. Childhood cancer survivors, especially, suffer multiple chronic health impairments. The incidence of these late treatment consequences appears to have no plateau with age, throwing in stark relief the necessity of close monitoring and therapies with fewer late consequences of treatment. John W. Adamson"
        },
        {
            "id": "Pharmacology_Katzung_5869",
            "title": "Pharmacology_Katzung",
            "content": "Neoadjuvant chemotherapy refers to the use of chemotherapy in patients who present with localized cancer for which alternative local therapies, such as surgery, exist but which have been shown to be less than completely effective. At present, neoadjuvant therapy is most often administered in the treatment of anal cancer, bladder cancer, breast cancer, gastroesophageal cancer, laryngeal cancer, locally advanced non-small cell lung cancer (NSCLC), osteogenic sarcoma, and locally advanced rectal cancer. For diseases such as anal cancer, gastroesophageal cancer, laryngeal cancer, NSCLC, and rectal cancer, optimal clinical benefit is derived when chemotherapy is administered with radiation therapy either concurrently or sequentially. The goal of the neoadjuvant approach is to reduce the size of the primary tumor so that surgical resection can be made easier and more effective. In addition, with rectal cancer and laryngeal cancer, the administration of combined modality ther apy prior to"
        },
        {
            "id": "Surgery_Schwartz_2313",
            "title": "Surgery_Schwartz",
            "content": "with metastatic mela-noma.156,157 Nivolumab and pembrolizumab are antibodies that target PD-1, whereas blockade of PD-L1 is accomplished with agents such as atezolizumab.158 Cancers for which checkpoint inhibitors have found utility include melanoma, renal cell car-cinoma, bladder carcinoma, squamous cell carcinoma of the head and neck, and carcinoma of the lung. These agents pro-duce durable shrinkage of advanced disease in 20% to 40% of patients, and combination strategies that employ checkpoint inhibitors with cytokines, vaccines, cellular therapies, and other targeted agents are under active investigation.GENE THERAPYGene therapy is being pursued as a possible approach to modify-ing the genetic program of cancer cells as well as treating meta-bolic diseases. The field of cancer gene therapy uses a variety of strategies, ranging from replacement of mutated or deleted tumor-suppressor genes to enhancement of immune responses to cancer cells.159 Indeed, in preclinical models,"
        },
        {
            "id": "Gynecology_Novak_7036",
            "title": "Gynecology_Novak",
            "content": "Stages IVA and IVB Cancer Primary exenteration may be considered for patients with direct extension to the rectum or bladder, but it is rarely performed. For patients with extension to the bladder, the survival rate with radiation therapy is as high as 30%, with a urinary fistula rate of only 3.8% (159). The presence of tumor in the bladder may prohibit cure with radiation therapy alone; thus, consideration must be given to removal of the bladder on completion of external beam radiation treatment. This is particularly true if the disease persists at that time and the geometry is not conducive to brachytherapy. Rectal extension is less commonly observed but may require diversion of the fecal stream before chemoradiation to avoid septic episodes from fecal contamination. In certain clinical situations, such as with patients who have stage IVA disease and present with vesicovaginal or rectovaginal fistula, urinary or rectal diversion may be performed, followed by chemoradiation."
        },
        {
            "id": "InternalMed_Harrison_7366",
            "title": "InternalMed_Harrison",
            "content": "A partial cystectomy may be considered when the disease is limited to the dome of the bladder, a \u22652 cm margin can be achieved, there is no associated CIS, and the bladder capacity is adequate after resection. This occurs in 5\u201310% of cases. Carcinomas in the ureter or in the renal pelvis are treated with nephroureterectomy with a bladder cuff to remove the tumor. The probability of recurrence following surgery is based on pathologic stage, presence or absence of lymphatic or vascular invasion, and nodal spread. Among those whose cancers recur, the recurrence develops in a median of 1 year. Long-term outcomes vary by pathologic stage and histology (Table 114-1). The number of lymph nodes removed is also prognostic, whether or not the nodes contained tumor."
        },
        {
            "id": "InternalMed_Harrison_6597",
            "title": "InternalMed_Harrison",
            "content": "The treatment for patients with stage IV melanoma has changed dramatically in the past 2 years. Two new classes of therapeutic agents for melanoma have been approved by the U.S. Food and Drug Administration (FDA). The immune T cell checkpoint inhibitor, ipilimumab, and three new oral agents that target the MAP kinase pathway: the BRAF inhibitors, vemurafenib and dabrafenib, and the Surgery: Metastasectomy for small number of lesions Immunotherapy: Anti-CTLA-4: ipilimumab Anti-PD-1: nivolumab, lambrolizumab Molecular targeted therapy: BRAF inhibitor: vemurafenib, dabrafenib MEK inhibitor: trametinib Chemotherapy: dacarbazine, temozolomide, paclitaxel, albumin-bound paclitaxel (Abraxane), carboplatin MEK inhibitor, trametinib, are now available, so patients with stage IV disease now have multiple therapeutic options (Table 105-4)."
        },
        {
            "id": "InternalMed_Harrison_7362",
            "title": "InternalMed_Harrison",
            "content": "The treatment of a tumor that has invaded muscle can be separated into control of the primary tumor and systemic chemotherapy to treat micrometastatic disease. Radical cystectomy is the standard treatment in the United States, although in selected cases, a bladder-sparing approach is used. This approach includes complete endoscopic resection; partial cystectomy; or a combination of resection, systemic chemotherapy, and external beam radiation therapy. In some countries, external beam radiation therapy is considered standard. In the United States, it is generally limited to those patients deemed unfit for cystectomy, those with unresectable local disease, or as part of an experimental bladder-sparing approach."
        },
        {
            "id": "Pathoma_Husain_374",
            "title": "Pathoma_Husain",
            "content": "4. Hypertrophy of bladder wall smooth muscle; increased risk for bladder diverticula 5. Microscopic hematuria may be present. 6. Prostate-specific antigen (PSA) is often slightly elevated (usually less than 10 ng/ mL) due to the increased number of glands; PSA is made by prostatic glands and liquefies semen. F. Treatment 1. a -antagonist (e.g., terazosin) to relax smooth muscle i. Also relaxes vascular smooth muscle lowering blood pressure ii. Selective a A -antagonists (e.g., tamsulosin) are used in normotensive individuals to avoid a effects on blood vessels. 2. 5a-reductase inhibitor i. Blocks conversion of testosterone to DHT ii. Takes months to produce results iii. Also useful for male pattern baldness iv. Side effects are gynecomastia and sexual dysfunction. V. PROSTATE ADENOCARCINOMA A. Malignant proliferation of prostatic glands B. Most common cancer in men; 2nd most common cause of cancer-related death"
        },
        {
            "id": "InternalMed_Harrison_10741",
            "title": "InternalMed_Harrison",
            "content": "patients, use of a longterm indwelling bladder catheter is a well-documented risk factor for bladder cancer. Chronic bacteriuria resulting in chronic inflammation is one possible explanation for this observation."
        },
        {
            "id": "Gynecology_Novak_6980",
            "title": "Gynecology_Novak",
            "content": "Table 36.5 Comparison of Surgery versus Radiation for Stage IB/IIA Cancer of the Cervix to treat the pelvic lymph nodes. Larger lesions require external radiotherapy first to shrink the tumor and to reduce the anatomic distortion caused by the cancer. Such a treatment strategy enables the therapist to achieve intracavitary dosimetry. The usual doses delivered are 7,000 to 8,000 cGy to point A (defined as 2 cm superior to the external cervical os and 2 cm lateral to the internal uterine canal) and 6,000 cGy to point B (defined as 3 cm lateral to point A), limiting the bladder and rectal dosage to less than 6,000 cGy. To achieve this level, it is necessary to adequately pack the bladder and bowel away from the intracavitary source. Localization films and careful calculation of dosimetry are mandatory to optimize the dose of radiation and to reduce the incidence of bowel and bladder complications. Local control depends on delivering an adequate dose to the tumor from the intracavitary"
        },
        {
            "id": "InternalMed_Harrison_25602",
            "title": "InternalMed_Harrison",
            "content": "amount of fluid throughout the day in order to maintain a dilute urine can reduce the risk of bladder injury. Bladder cancer can occur several years after discontinuation of cyclophosphamide therapy; therefore, monitoring for bladder cancer should continue indefinitely in patients who have received cyclophosphamide. Bone marrow suppression is an important toxicity of cyclophosphamide and can be observed during glucocorticoid tapering or over time, even after periods of stable measurements. Monitoring of the complete bloodcountevery1\u20132weeks foraslong asthepatient receives cyclophosphamide can effectively prevent cytopenias. Maintaining the white blood cell (WBC) count at >3000/\u03bcL and the neutrophil count at >1500/\u03bcL is essential to reduce the risk of life-threatening infections."
        }
    ],
    "scores": [
        0.039603960396039604,
        0.03346286585682176,
        0.025007164927210616,
        0.02351127991754781,
        0.022821340617950783,
        0.02272400555419423,
        0.02230606571035282,
        0.02218206081764825,
        0.021828584110611546,
        0.020534111574574004,
        0.02000166680556713,
        0.019148138391914246,
        0.019142700128228614,
        0.018653479090751345,
        0.01789280293953191,
        0.01746031746031746,
        0.01734232565033721,
        0.0167013167013167,
        0.016609706083390293,
        0.016523867809057527,
        0.01634612821053499,
        0.016317169069462647,
        0.016146326080100915,
        0.01597542242703533,
        0.015802318486882246,
        0.01525900900900901,
        0.015194244604316547,
        0.015097092827477832,
        0.015006385696040868,
        0.01488095238095238,
        0.014875027648750276,
        0.014823717948717948
    ]
}